NovaDigm cross-kingdom vaccine shows promise

NovaDigm Therapeutics, a pharmaceutical company specializing in vaccines to fight fungal and bacterial infections, recently announced positive results from a phase I study of a vaccine to against the fungus Candida and the bacterium Staphylococcus aureus.

The data from the study, which will be published in the journal Vaccine, shows that a single dose of the NDV-3 vaccine with an alum adjuvant is safe, well-tolerated and capable of inducing strong T-cell and antibody immune responses in adults, according to

NDV-4 is unique as the first vaccine to demonstrate preclinical cross-kingdom efficacy against both bacterial and fungal parasites when compared to a placebo.

"The publication of this positive data provides further validation for NovaDigm as we prepare to begin a Phase 2 efficacy study with an optimized vaccine formulation in the first half of 2013," NovaDigm CEO Dr. Timothy Cooke said, reports. "We are encouraged that NDV-3 was shown to be safe and well-tolerated, with a very promising immunogenicity profile, in two Phase 1 studies.

"We are confident that it can play an important role in treating community- and hospital- acquired infections caused by these pathogens, which represent significant medical needs and large commercial potential."

Both Candida and Staph aurea are capable of causing a wide array of infections.